Down Syndrome (DS)
15
9
10
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
27%
4 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (15)
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
The Impact of Core Stability Versus Respiratory Muscle Strengthening Exercises on Bone Mineral Density in Children With Down Syndrome
Adapting RDAD for DS
Effects of a Structured Physical Activity Program on Balance and Functional Performance in Children With Down Syndrome
Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome
Effects of Chronic Creatine and Beta-Hydroxy-Beta-Methylbutyrate Supplementation on Oxidative Stress, Inflammation, Muscle Strength, and Body Composition in Individuals With Down Syndrome
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome
The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia
The Effect of the HEP Approach in Infants With Down Syndrome
Awareness of Families With Down Syndrome Children About the Role of Physical Therapy in Egypt
Using Technologies to Promote HEalthy Lifestyles in Adolescents With Intellectual Disabilities
Pediatric Down Syndrome Post-Approval Study
Suspension Therapy Effects on Mobility and Balance in Down Syndrome
Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool